Craft

Ionis Pharmaceuticals

Stock Price

$41.5

2024-04-16

Market Capitalization

$6.1 B

2024-04-16

Revenue

$787.6 M

FY, 2023

Ionis Pharmaceuticals Summary

Company Summary

Overview
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA), TEGSEDI, a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra, a medicine used to treat familial chylomicronaemia syndrome (FCS).
Type
Public
Status
Active
Founded
1989
HQ
Carlsbad, CA, US | view all locations
Website
http://www.ionispharma.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Brett P. Monia

    Brett P. Monia, Chief Executive Officer, Director

  • Onaiza Cadoret-Manier

    Onaiza Cadoret-Manier, Executive Vice President, Chief Product Strategy and Operations Officer

  • C. Frank Bennett

    C. Frank Bennett, Executive Vice President, Chief Scientific Officer

  • Eric E. Swayze

    Eric E. Swayze, Executive Vice President, Research

Operating MetricsView all

Manufacturing Facility Space, sq. ft.

26.8K
6.6%

FY, 2020

Phase I Trials Products

6
50.0%

FY, 2020

Phase II Trials Products

24
41.2%

FY, 2020

LocationsView all

1 location detected

  • Carlsbad, CA HQ

    United States

    2855 Gazelle Ct

Ionis Pharmaceuticals Financials

Summary Financials

Revenue (FY, 2023)
$787.6M
Gross profit (FY, 2023)
$778.5M
Net income (FY, 2023)
($366.3M)
Cash (FY, 2023)
$399.3M
EBIT (FY, 2023)
($353.7M)
Enterprise value
$6.9B

Footer menu